Investigation the effect of trehalose on PSP

Investigation of the effect of trehalose on symptoms of a PSP (progressive supranuclear palsy) patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041407N5

Enrollment

Registered

2024-06-06

Start date

2024-07-22

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PSP (progressive supranuclear palsy). Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

Interventions

Intervention group: IV Trehalose (15 g per week) for 12 weeks by Dr.Rajabi Pharmaceutical Co..

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with PSP diagnosis (according to NINDS-PSP criteria) Satisfaction for participation in the research project

Exclusion criteria

Exclusion criteria: Uncontrolled and severe adverse event

Design outcomes

Primary

Measure	Time frame
Patient`s Function. Timepoint: Baseline and after 3 months. Method of measurement: Using the PSP rating scale (PSP-RS).	—

Secondary

Measure	Time frame
Interleukin-6 (IL-6). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.;C-Reactive Protein (CRP). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.;Neutrophil-to-lymphocyte ratio (NLR). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026